Table of Contents Table of Contents
Previous Page  117 / 280 Next Page
Information
Show Menu
Previous Page 117 / 280 Next Page
Page Background

How do you see the importance of biobanking

developing between now and 2020?

We think that samples and the treatment of data obtained through

biobanking activities could be a way to revolutionise the pharmaceutical

market. Indeed, one of the aims of the pharmaceutical groups in investing

time and money into biobanking is to relevantly reduce the duration of

drug development and the number of necessary preclinical studies. To

achieve this, some researchers are starting to model the result of drug

actions by using the data collected through previous research studies.

What future developments do you see taking place?

Regarding our work as a biorepository service provider, we are convinced

that, over the next few years, operational and detailed radio frequency

Identification development, for example temperature and volume, will

significantly improve the ways to collect and manage biosamples.

Another major area will be the standardisation of analytical methods for

the evaluation of the sample quality. This is one of the major challenges

– how to evaluate the quality of the samples and how to determine their

degradation through time. But we also need to develop standard methods

for cryopreservation and samples processing.

Biobanking offers a wide range of innovative perspectives, but

standardisation and collaboration will be key to the success of this

research sector. Biobanking is identified as a costly actor in this domain,

and this therefore requires biobanking actors to innovate in order to

reduce its operating costs.

Everyone agrees on the need to standardise

biobanking activity, but interests and points of

view vary from one country to another. The

challenge for the working group and the ISO will

be to develop an ISO norm suiting the needs of

the biobanking market and accepted by every

actor involved in its application.

What recent efforts have been

made to overcome the difficulties

in the standardisation of the

identification and traceability of

data in the sector?

In France, the NFS 96-900 certification (French

certification for biological resource centre

(BRC)) activities was settled in 2002.

Nowadays, around 100 BRCs, Cell & Co

included, have been certified. This has

improved exchange between the BRCs and has

permitted them to establish qualitative

operational methods. The results produced and

the sample generated have better value and

allow the BRCs to work more easily with

external collaborators.

This spreading of the NFS 96-900 certification

has been supported by ‘Infrastructure

Biobanques’, which was created in 2011 with

the help of the French Government.

What further attempts can be made

in overcoming these

standardisation issues?

In parallel to the establishment of the ISO for

biobanking, it appears necessary to work on the

establishment of a standard terminology that

would allow the biobanking actors and

database to cross their data more easily. This

work would have to be performed by targeted

pathology, by type of samples, by type of

projects, etc. Several attempts have been

performed with this aim, but this work is still

unachieved and must be extended.

What role do you see biobanking

playing in Horizon 2020?

Every clinical and cohort study performed

through Horizon 2020 should implicate the

generation of a qualitative biocollection that

might be valued by other researchers. The EU’s

research and innovation framework programme

has then a role to play in the evaluation of the

research schemes that do not anticipate this

need or underestimate the requirements,

notably in terms of a database and the

establishment of a valuable biocollection.

Florent Belon

Sofien Dessolin

Cell & Co

B R OW S E

www.cell-and-co.com

H O R I Z O N

2 0 2 0

www.horizon2020projects.com

H O R I Z O N 2 0 2 0 P R O J E C T S : P O R TA L

I S S U E S E V E N

117

H E A L T H & P AT I E N T D ATA

Standardisation is

currently a major

issue in

European biobanking